1215PT cell repertoire sequencing reveals dynamics of response to dendritic cell vaccine plus dasatinib for checkpoint blockade resistant metastatic melanoma

ConclusionsThese data suggest that peripheral blood TCRB convergence may serve as a predictive or prognostic biomarker for response to dendritic cell-based immunotherapy. Our finding of increased T cell clonal expansion at week 5 of treatment supports the notion that TCR sequencing may serve as a tool for the measurement of pharmacodynamic markers of therapeutic agent activity. Ongoing and future studies will further clarify the utility of TCR convergence and clonal expansion as immune repertoire biomarkers.Clinical trial identificationNCT01876212.Legal entity responsible for the studyUniversity of Pittsburgh School of Medicine&Hillman Cancer Center.FundingThermo Fisher Scientific.DisclosureL. Quagliata: Full / Part-time employment: Thermo Fisher Scientific. T. Looney: Full / Part-time employment: Thermo Fisher Scientific. D. Topacio-Hall: Full / Part-time employment: Thermo Fisher Scientific. G. Lowman: Full / Part-time employment: Thermo Fisher Scientific. All other authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

This study provides strong evidence that following a healthy lifestyle can substantially extend the years a person lives disease-free." Commentary on Recent Evidence for Cognitive Decline to Precede Amyloid Aggregation in Alzheimer's Disease https://www.fightaging.org/archives/2020/01/commentary-on-recent-evidence-for-cognitive-decline-to-precede-amyloid-aggregation-in-alzheimers-disease/ I can't say that I think the data presented in the research noted here merits quite the degree of the attention that it has been given in the popular science press. It is interesting, but not compelling if its role...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Hui Zhou, Xiaoyan Fu, Qian Li and Ting Niu* Department of Hematology and Research Laboratory of Hematology, West China Hospital, Sichuan University, Chengdu, China Background: Immune checkpoint inhibition therapy with monoclonal antibody against programmed cell death protein 1 (PD-1), including nivolumab and pembrolizumab, has demonstrated powerful clinical efficacy in the treatment of advanced cancers. However, there is no evidence-based systematic review on the safety and efficacy of anti-PD-1 antibody in treating lymphoma. Methods: To evaluate the safety and efficacy of nivolumab/pembrolizumab, we analyzed clin...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Reena Goswami1, Gayatri Subramanian2, Liliya Silayeva1, Isabelle Newkirk1, Deborah Doctor1, Karan Chawla2, Saurabh Chattopadhyay2, Dhyan Chandra3, Nageswararao Chilukuri1 and Venkaiah Betapudi1,4* 1Neuroscience Branch, Research Division, United States Army Medical Research Institute of Chemical Defense, Aberdeen, MD, United States 2Department of Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, United States 3Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States 4Department of Physiology and Biophysics, Case Western Reserve University, Clev...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In this study, T cells deficient in TRAF6 display enhanced T cell activation, CD28-indpendent stimulation and resistance to Treg cell-mediated suppression (176). Although TLR signaling can promote T cell resistance to Treg cells, the precise molecular mechanism remains yet to be elucidated. It is worth noting that TLR stimulation of T cells increases cytokine production (173, 177), thus future studies should delineate the effect of TLR-MyD88 signaling vs. subsequently induced cytokines in generating resistance to Treg cells. Lastly, it is also crucial to evaluate the effect of TLR signaling on regulatory T cells which also...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Heinz Kohler1*, Anastas Pashov2 and Thomas Kieber-Emmons3 1Department of Microbiology and Immunology, University of Kentucky, Lexington, KY, United States2Stephan Angelov Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria3Department of Pathology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, United States The promise of idiotype-based therapeutics has been disappointing forcing a new look at the concept and its potential to generate an effective approach for immunotherapy. Here, the idiotype network theory is revisited with regard to...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
In this study, we have investigated the efficacy of the nanoparticle platform technology based on plant-derived Cowpea mosaic virus like particles (empty CPMV or eCPMV) to instigate a potent immune response against intracranial glioma. CPMV immunotherapy has been shown to efficiently reverse the immunosuppressive tumor microenvironments in pre-clinical murine models of dermal melanoma and metastatic melanoma, metastatic breast cancer, intraperitoneal ovarian cancer and in canine patients with oral melanoma. In the present study, we demonstrate that in situ administration of CPMV immunotherapy in the setting of glioma can e...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Recent breakthrough in checkpoint blockade drugs achieved remarkable success in treating late stage tumors, although a substantial fraction of patients failed to respond. Despite growing efforts, the clinical and molecular prognostic predictors of immunotherapy response remain elusive. We developed a novel computational method to deconvolute six tumor-infiltrating immune cells from the molecular profiles of over 10,000 samples across 23 cancer types, and validated the estimates using simulations, orthogonal estimates, and pathology. Correlating the computationally-inferred immune infiltrates with patient clinical features,...
Source: Molecular Cancer Therapeutics - Category: Cancer & Oncology Authors: Tags: Tumor Immunology Targets: Oral Presentations - Proffered Abstracts Source Type: research
Prevention of infectious diseases through immunization is one of the greatest achievements of modern medicine. Nonetheless, considerable challenges remain for improving the efficacy of vaccines currently employed to treat devastating diseases such as cancer. Dendritic cells (DC) are considered professional antigen-presenting cells of the immune system highly effective in initiating primary immune responses. Following infection or inflammation they undergo a complex process of maturation, and migrate to lymph nodes (LN) where they present antigens to T cells. Their decisive role in inducing immunity formed the rationale for...
Source: Molecular Cancer Therapeutics - Category: Cancer & Oncology Authors: Tags: Immune Response to Therapies: Oral Presentations - Invited Abstracts Source Type: research
Adoptive immunotherapy of T cells may have significant advantages over alternative immunotherapeutic approaches such as cancer vaccines since the phenotype, activity and specificity of expanded cells can be analyzed prior to injection. T cells can be genetically engineered prior to infusion to modify the antigens they target, increase their potency, and reduce their susceptibility to tumor-mediated immune inhibition. Genetic modification also allows T cells to be tracked in vivo to learn their fate. Adoptive transfer of T cells has been most successful after hematopoietic stem cell transplantation (HSCT) as prophylaxis and...
Source: Molecular Cancer Therapeutics - Category: Cancer & Oncology Authors: Tags: Other Topics: Oral Presentations - Invited Abstracts Source Type: research
This article reviews the immunological similarities between CMM and the human counterpart; mechanisms by which tumours evade the immune system; reasons why melanoma is an attractive target for immunotherapy; the premise of whole cell, dendritic cell (DC), viral and DNA vaccination strategies alongside preliminary clinical results in dogs. Current “gold standard” treatments for advanced human malignant melanoma are evolving quickly with remarkable results being achieved following the introduction of immune checkpoint blockade and adoptively transferred cell therapies. The rapidly expanding field of cancer immuno...
Source: Veterinary Immunology and Immunopathology - Category: Veterinary Research Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Clinical Trials | Employment | Immunotherapy | Legislation | Melanoma | Oral Cancer | Skin Cancer | Students | Study | Universities & Medical Training | Vaccines